CIDRAP newsletters options
Europe's COVID-19 cases have dropped 60% in the past month, but progress is fragile.
"The CDC got the science right, but the policy and communication was really wrong."
One in seven US adult COVID-19 patients developed at least one new illness requiring medical care after recovery from their infection in 2020, finds an observational study yesterday in BMJ.
Antibiotic prescribing for young children in Israel sharply declined following implementation of pneumococcal conjugate vaccine (PCV), Israeli researchers reported today in Clinical Infectious Diseases.
Argentina reports record deaths as activity continues to flare in places like Brazil, areas of Central America, and some Caribbean islands.
Multisystem inflammatory syndrome has a different presentation in adults than in kids and may be missed.
For the first time in 14 months, most businesses in New York City can return to full capacity.
Long-haul COVID-19 was associated with severe or very severe symptoms, low income, and some age-groups, but was common even in those with mild symptoms, with a quarter of patients in that group having symptoms after 60 days, according to a Clinical Infectious Diseases study today that looked at adult Michigan patients.
CARB-X announced today that it is awarding Swiss drug maker Basilea Pharmaceutica International up to $2.7 million to develop a novel class of antibiotics to treat gram-negative bacterial infections.
Some other Asian nations are facing their biggest surges of the pandemic, and 7 African nations report notable rises.
Though the pandemic is ebbing in the US, those getting sick and hospitalized are skewing younger.
One study evaluates vaccine allocation plans, and the other reveals urban vs rural inequities.
The rate of multidrug-resistant organisms in organic meat was more than 50% lower than in conventional.
CARB-X announced today that it is awarding up to $4.1 million to Summit Therapeutics of Cambridge, Massachusetts, to develop a first-in-class antibiotic to treat multidrug-resistant bacterial infections.
Fewer high-risk outpatients with mild or moderate COVID-19 needed hospitalization or died within 28 days when given bamlanivimab soon after infection compared with their matched peers, finds an observational study yesterday in Open Forum Infectious Diseases.
Convalescent plasma did not improve survival or other important outcomes.
"While the situation in India is tragic, it is not unique." Surging cases are taxing healthcare systems.
For the first time since the pandemic started, all states are reporting declining cases.
An investigation into a Listeria moncytogenes outbreak linked to a New Jersey company's queso fresco cheese has ended, with 14 cases reported in four states, the US Centers for Disease Control and Prevention (CDC) said May 14 in a final update.
Almost two thirds of homeless patients hospitalized for COVID-19 were of non-White descent and more than 80% had at least one comorbidity, according to a descriptive study in The Journal of Infectious Diseases yesterday.
